Logical structures extracted from metastasis experiments

Cancer Science

Volumn 100, Issue 11, 2009, Pages 2006-2013

  Maru, Yoshiro ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BEVACIZUMAB; CALGRANULIN A; CALGRANULIN B; CHEMOKINE RECEPTOR CXCR4; CLODRONIC ACID; CUTANEOUS T CELL ATTRACTING CHEMOKINE; GELATINASE B; MYC PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OXALIPLATIN; RAS PROTEIN; SERUM AMYLOID A; SERUM AMYLOID A3; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC THERAPY; BONE DESTRUCTION; BONE METASTASIS; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CYTOKINE RELEASE; DISTANT METASTASIS; HUMAN; INFLAMMATION; INNATE IMMUNITY; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS; METASTASIS INHIBITION; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; UPREGULATION;

ANIMALS; CALGRANULIN A; HUMANS; NEOPLASM METASTASIS; SERUM AMYLOID A PROTEIN; TOLL-LIKE RECEPTOR 4; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 71049154836     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01300.x     Document Type: Review

References (72)

1. Schirrmacher V. Cancer metastasis: experimental approaches, theoretical concepts, and impacts for treatment strategies. Adv Cancer Res 1985, 43:1-73.
2. Steeg PS, de la Rosa A, Flatow U, MacDonald NJ, Benedict M, Leone A. Nm23 and breast cancer metastasis. Breast Cancer Res Treat 1993, 25:175-87.
3. Steeg PS, Bevilacqua G, Kopper L. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988, 80:200-4.
4. Kang Y, Siegel PM, Shu W. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-49.
5. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449:682-8.
6. Tavazoie SF, Alarcón C, Oskarsson T. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451:147-52.
7. Reya T, Morrison SJ, Clarke MF, Weisman IL. Stem cells, acncer, and cancer stem cells. Nature 2001, 414:105-11.
8. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007, 448:313-7.
9. Podsypanina K, Du YC, Jechlinger M, Beverly LJ, Hambardzumyan D, Varmus H. Seeding and propagation of untransformed mouse mammary cells in the lung. Science 2008, 321:1841-4.
10. van 't Veer LJ, Dai H, van de Vijver MJ. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-6.
11. Wang J, Loberg R, Taichman RS. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev 2006, 25:573-87.
12. Kaplan RN, Riba RD, Zacharoulis S. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-7.
13. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006, 8:1369-75.
14. Anderson ARA, Weaver AM, Cummings PT, Quaranta V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 2006, 127:905-15.
15. Hiratsuka S, Watanabe A, Sakurai Y. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 2008, 10:1349-55.
16. Rosol TJ, Tannehill-Gregg SH, LeRoy BE, Mandl S, Contag CH. Animal models of bone metastasis. Cancer 2003, 97:748-57.
17. Blouin S, Baslé MF, Chappard D. Rat models of bone metastases. Clin Exp Metastasis 2005, 22:605-14.
18. Yonou H, Yokose T, Kamijo T. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res 2001, 61:2177-82.
19. Fidler IJ. Metastasis: guantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2′-deoxyuridine. J Natl Cancer Inst 1970, 45:773-82.
20. Hiratsuka S, Nakamura K, Iwai S. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002, 2:289-300.
21. Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS. Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 2006, 396:201-14.
22. Ehrchen JM, Sunderkötter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009, 86.
23. Bouma G, Lam-Tse WK, Wierenga-Wolf AF, Drexhage HA, Versnel MA. Increased serum levels of MRP-8/14 in type 1 diabetes induce an increased expression of CD11b and an enhanced adhesion of circulating monocytes to fibronectin. Diabetes 2004, 53:1979-86.
24. Itou H, Yao M, Fujita I. The crystal structure of human MRP14 (S100A9), a Ca(2+)-dependent regulator protein in inflammatory process. J Mol Biol 2002, 316:265-76.
25. Passey RJ, Williams E, Lichanska AM. A null mutation in the inflammation-associated S100 protein S100A8 causes early resorption of the mouse embryo. J Immunol 1999, 163:2209-16.
26. Hermani A, De Servi B, Medunjanin S, Tessier PA, Mayer D. S100A8 and S100A9 activate MAP kinase and NF-γB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res 2006, 312:184-97.
27. Robinson MJ, Tessier P, Poulsom R, Hogg N. The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells. J Biol Chem 2002, 277:3658-65.
28. Vogl T, Tenbrock K, Ludwig S. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007, 13:1042-9.
29. Gebhardt C, Riehl A, Durchdewald M. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008, 205:275-85.
30. Stern DM, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 2002, 1:1-15.
31. Kerkhoff C, Nacken W, Benedyk M, Dagher MC, Sopalla C, Doussiere J. The arachidonic acid-binding protein S100A8/A9 promotes NADPH oxidase activation by interaction with p67phox and Rac-2. FASEB J 2005, 19:467-9.
32. Zou N, Ao L, Cleveland JC. Critical role of extracellular heat shock cognate protein 70 in the myocardial inflammatory response and cardiac dysfunction after global ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2008, 294:H2805-13.
33. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system?. Semin Immunol 1996, 8:271-80.
34. Keller M, Rüegg A, Werner S, Beer HD. Active caspase-1 is a regulator of unconventional protein secretion. Cell 2008, 132:818-31.
35. Akashi S, Saitoh S, Wakabayashi Y. Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J Exp Med 2003, 198:1035-42.
36. Gilchrist M, Thorsson V, Li B. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature 2006, 441:173-8.
37. Lu D, Chen J, Hai T. The regulation of ATF3 gene expression by mitogen-activated protein kinases. Biochem J 2007, 401:559-67.
38. Beutler BA. TLRs and innate immunity. Blood 2009, 113:1399-407.
39. Bhide MR, Mucha R, Mikula I. Novel mutations in TLR genes cause hyporesponsiveness to Mycobacterium avium subsp. paratuberculosis infection. BMC Genet 2009, 10:21.
40. van Zoelen MA, Schouten M, de Vos AF. The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol 2009, 182:4349-56.
41. Suganami T, Tanimoto-Koyama K, Ogawa Y. Role of the Toll-like receptor 4/NF-γB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 2007, 27:84-91.
42. Jiang D, Liang J, Fan J. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005, 11:1173-9.
43. Kim S, Takahashi H, Lin WW. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009, 457:102-6.
44. Chen R, Alvero AB, Silasi DA, Steffensen KD, Mor G. Cancers take their Toll - the function and regulation of Toll-like receptors in cancer cells. Oncogene 2008, 27:225-33.
45. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007, 13:552-9.
46. Broxmeyer HE. Chemokines in hematopoiesis. Curr Opin Hematol 2008, 15:49-58.
47. Lu DY, Tang CH, Yeh WL. SDF-1α up-regulates interleukin-6 through CXCR4, PI3K/Akt, ERK, and NF-γB-dependent pathway in microglia. Eur J Pharmacol 2009, 613:146-54.
48. Han Y, He T, Huang DR, Pardo CA, Ransohoff RM. TNF-α mediates SDF-1α-induced NF-γ B activation and cytotoxic effects in primary astrocytes. J Clin Invest 2001, 108:425-35.
49. Ang E, Pavlos NJ, Rea SL. Proteasome inhibitors impair RANKL-induced NF-γB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IγBα signaling cascades. J Cell Physiol 2009, 220:450-9.
50. Mikami S, Katsube KI, Oya M. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J Pathol 2009, 218:530-539.
51. Padua D, Zhang XH, Wang Q. TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008, 133:66-77.
52. Guise TA. Parathyroid hormone-related protein and bone metastases. Cancer 1997, 80:1572-80.
53. Massagué J. TGFβ in Cancer. Cell 2008, 134:215-30.
54. Jones DH, Nakashima T, Sanchez OH. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006, 440:692-6.
55. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-72.
56. Saltz LB, Clarke S, Díaz-Rubio E. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-9.
57. Stockmann C, Doedens A, Weidemann A. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008, 456:814-8.
58. Orimo A, Gupta PB, Sgroi DC. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-48.
59. Deshane J, Chen S, Caballero S. Stromal cell-derived factor 1 promotes angiogenesis via a heme oxygenase 1-dependent mechanism. J Exp Med 2007, 204:605-18.
60. Shojaei F, Wu X, Zhong C. Bv8 regulates myeloid-cell-dependent tumor angiogenesis. Nature 2007, 450:825-31.
61. Hiraoka K, Zenmyo M, Watari K. Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci 2008, 99:1595-602.
62. Kaplan RN, Psaila B, Lyden D. Bone marrow cells in the 'pre-metastatic niche': within bone and beyond. Cancer Metastasis Rev 2006, 25:521-9.
63. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006, 39:469-78.
64. Fragoso R, Pereira T, Wu Y, Zhu Z, Cabeçadas J, Dias S. VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood 2006, 107:1608-16.
65. Maru Y, Yamaguchi S, Shibuya M. Flt-1, a receptor for vascular endothelial growth factor, has transforming and morphogenic potentials. Oncogene 1998, 16:2585-95.
66. Usui R, Shibuya M, Ishibashi S, Maru Y. Ligand-independent activation of VEGF receptor 1 by low density lipoprotein. EMBO Rep 2007, 8:1155-61.
67. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-44.
68. Nagai Y, Garrett KP, Ohta S. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 2006, 24:801-12.
69. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 2008, 84:623-30.
70. Turer EE, Tavares RM, Mortier E. Homeostatic MyD88-dependent signals cause lethal inflammation in the absence of A20. J Exp Med 2008, 205:451-64.
71. Walser TC, Rifat S, Ma X, Kundu N. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 2006, 66:7701-7.
72. Maru Y. Which came first, tumor cells or macrophages?. Cell Adh Migr 2007, 1:107-9.